Cellectis SA
(UNKNOWN : CLLS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.12%178.061.3%$463.32m
CELGCelgene Corporation
0.92%97.401.3%$421.98m
GILDGilead Sciences, Inc.
1.34%67.250.9%$393.71m
BIIBBiogen Inc.
2.27%232.841.3%$355.42m
ILMNIllumina, Inc.
2.11%351.273.5%$273.61m
REGNRegeneron Pharmaceuticals, Inc.
1.91%311.082.6%$233.37m
AAgilent Technologies, Inc.
0.63%70.411.6%$213.41m
VRTXVertex Pharmaceuticals Incorporated
2.17%173.921.9%$198.41m
ARRYArray BioPharma Inc.
57.13%46.498.2%$186.25m
EXASExact Sciences Corporation
0.94%110.8125.3%$184.59m
ALXNAlexion Pharmaceuticals, Inc.
2.26%120.592.0%$176.05m
BMRNBioMarin Pharmaceutical Inc.
4.16%84.214.3%$136.26m
MRTXMirati Therapeutics Inc.
6.98%100.842.5%$114.49m
IONSIonis Pharmaceuticals, Inc.
4.33%64.788.2%$97.13m
INCYIncyte Corporation
5.50%81.992.5%$92.11m

Company Profile

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.